RJ Hamster
New Finance Era – Breaking news for You
New Finance Era – Breaking news for You
— Read on newfinanceera.com/
RJ Hamster
RJ Hamster
RJ Hamster
3 Startups Leading American Innovation… and 8 More in…
3 Startups Leading American Innovation… and 8 More in the Wings
In the early days of Russia’s war in Ukraine, volunteers and charitable foundations began assembling small-scale drones to help Ukraine’s war effort. These do-it-yourself makers outfitted commercial racing drones with better cameras (and eventually explosive payloads) to track and pressure invading forces.
These cheap machines were startlingly effective. Drones could be piloted from hundreds of yards away to spot Russian tank positions and relay the coordinates to artillery teams. Other versions carried warheads, turning $350 drones into flying bombs.
In fact, drones proved so useful that the Ukrainian government soon developed Decree 256, which established the country’s “Army of Drones” project.
Today, drones have become the main anti-tank weapon in the Russian-Ukrainian war. More than half of the destruction on Ukraine’s front lines is credited to these unmanned machines, and its military uses them by the millions.
The same concepts are now being used by U.S. forces.
On January 3, Venezuelan residents reported hearing high-pitched buzzing noises right before major explosions at port facilities and military bases. Though the U.S. military has denied their use, social media videos suggest that the U.S. military used dozens (if not hundreds) of one-way “kamikaze” drones to attack Venezuelan targets while keeping American soldiers out of harm’s way. The assault created a diversion that allowed an American strike team to swoop in and capture Venezuela’s president and his wife.
The success of Operation Absolute Resolve put defense stocks into overdrive. Shares of the defense “primes” rose double digits following America’s intervention in Venezuela, while some smaller firms rose even more. Whether or not you agree with American military intervention, it’s undeniable that these firms will benefit from increased military spending.
We believe this is only the start. After all, defense primes were built to accept billion-dollar contracts for expensive fighter jets… not hundred-million-dollar orders for $350 drones. Instead, an entirely new generation of companies will emerge to fill this gap.
That’s why, over the past several weeks, Luke Lango and his team have combed through executive orders, pored over government memos, and spoken with military insiders to identify which companies are best positioned to receive U.S. government funding.
Their conclusion: It’s an endeavor on the scale of the Manhattan Project or Apollo Program.
Luke is calling it the “Genesis Mission.” This multiyear effort will see significant investments by the U.S. government in drone technologies and other critical areas. He identifies six core sectors that stand to gain:
- Artificial Intelligence
- Quantum Computing
- Nuclear Energy
- Biotech
- Semiconductors
- Advanced Manufacturing
He will go into more detail on Tuesday, January 27, where he will reveal more about the eight stocks in his Genesis Portfolio that focus on these sectors. (He’ll also tell us some about several privately held companies benefiting from the federal government’s new focus as well.)
Watch your inbox on Tuesday for a direct link to Luke’s free broadcast.
To illustrate the types of companies he’s eyeing, I’d like to revisit three of my picks from previous InvestorPlace Digestupdates that illustrate why investing in smaller innovative firms is so important for long-term success.
Recommended Link
“This Will Make AI Look Like a Pocket Calculator”
Louis Navellier, who picked Nvidia back in 2016 at $1 split-adjusted… Predicts this Nvidia new invention will be much bigger than AI. And Bank of America says this new technology could be… “The biggest revolution for humanity since discovering fire.” Click here to get the details.
A Promising Drone Startup
Last October, I highlighted Ondas Holdings Inc. (ONDS), a fast-growing provider of industrial wireless networks and commercial drones. It was the first company to receive certification by the Federal Aviation Administration for an automated aerial security drone and has continued to innovate with new products.
Most importantly, the West Palm Beach, Florida-based firm is behind a new “predator drone” system that targets other drones. Using a radar-guided system, Ondas’ experimental product locks onto other drones and fires a ballistic net at its target. A parachute then safely lowers the enemy drone to the ground.
This is a surprisingly useful innovation, because it would be madness to fire a flak cannon at an enemy drone flying near critical infrastructure or friendly units. In fact, there have been multiple reports of Russian forces mistakenly shooting down their own aircraft while attempting to repel Ukrainian drone strikes.
Ondas solves this problem by using a safer netting system, making it useful near airports, military facilities and public spaces. Shares of the firm have risen 180% since my original article, and there’s likely more room for growth as the firm seeks more bolt-on acquisitions.
In late November, for instance, Ondas announced it would acquire Roboteam, a startup involved in developing tactical ground robotics. They aim to create unmanned ground vehicles can be used for explosives ordinance disposal (EOD), route clearance, logistics support, and more. Ondas’ know-how in secure wireless communications should help this team succeed.
In addition, Ondas raised $1 billion earlier in January at an excellent valuation of $16.45 per share. This stock-and-warrant offering will help fund an enormous amount of production growth, and management now expects $175 million in revenues in 2026 – a 165% increase from 2025 levels.
These are the types of investments that even conservative investors like me tend to appreciate. The company has a rapidly growing backlog (which provides real revenues), and analysts are projecting positive EBITDA profits as soon as 2027.
The Biotech Wonders
Meanwhile, not every U.S. innovation will involve the military. In fact, Wall Street’s recent focus on defense companies means that some of Luke’s other six sectors have been completely ignored.
Here, my favorite sector is biotech, an area that investors often ignore due to its perceived risk.
In fact, one of my favorite biotech bets, Greenwich LifeSciences Inc. (GLSI) has already jumped 200% since I called the stock a “Buy” last November. The firm’s flagship therapy previously showed compelling results in its Phase IIb and initial Phase III trials, making it an unusually safer bet for a successful Phase III finale. (I write “safer” becasue there’s no such thing as a sure bet in biotech until regulators give the final seal of approval.)
However, as big bets go… that award goes to two companies developing gene-editing platforms — a technology I believe will power the next generation of innovative drugs.
My top pick here is Crispr Therapeutics AG (CRSP), a company founded by the inventors of the “scissors” used by most gene-editing firms. The Swiss company lands among my Top 8 picks for 2026, and shares have already risen 5% since I recommended it several short weeks ago. It is the only gene-editing firm with an approved product on the market, and I expect Crispr’s sickle cell therapy to become a billion-dollar blockbuster in the coming years.
My other bet in this space is Intellia Therapeutics Inc. (NTLA), a riskier firm that was forced to pause a clinical trial in October after a patient experienced severe liver injury. Unlike Crispr, Intellia does not have an approved product on the market yet.
However, its smaller starting size (its market cap is less than a third of CRSP’s) and 100% ownership of a separate drug, NTLA-2002, give it far greater upside if things go well. Shares rose as much as 147% when I first highlighted it as a potential 1,000% winner last September,and even its clinical trial pause has left its stock 33% higher since last year.
The U.S. government is now lending a helping hand to the industry.
In November, the Food and Drug Administration (FDA) unveiled a new regulatory roadmap that should turbocharge the development of gene-editing drugs, especially for rarer genetic disorders. Under new rules, drugs that target rarer disorders (or those that must be customized for individual users) may skip large-scale clinical trials entirely.
This would be game-changing, because it’s often impossible to recruit enough people to run a traditional large-scale trial. In fact, traditional clinical trials are impossible if you only have one patient.
That’s why I believe CRSP and NTLA continue to have incredible upside. The U.S. government is starting to uncork innovation in other areas besides AI, and companies like ONDS, CRSP, and NTLA should benefit as a direct result.
The Genesis Portfolio
Those who follow Luke Lango will know how he’s recommended dozens of innovative stocks long before they hit mainstream media. He’s identified companies like:
- Celestica Inc. (CLS): +264% since March 2025
- BWX Technologies Inc (BWXT):+143% since February 2024
- Palantir Technologies Inc. (PLTR):+971% since June 2023
These three particular stocks count the U.S. government as a key customer.
- Celestica is a crucial supplier of the electronic components found in aircraft, ships, and unmanned vehicles.
- Micro nuclear reactor firm BWXT was recently awarded a $1.6 billion contract to produce high-purity depleted uranium for national defense purposes.
- And Palantir provides software that helps the U.S. military make AI-powered predictions.
That’s put these firms on hypergrowth tracks. In fact, Palantir is expected to grow another 53% this year, thanks to insatiable demand for its AI-powered data analysis.
This isn’t the first time the U.S. government has intervened in American industry. During the First and Second World Wars, the federal government coordinated the production of steel, rail, trains, and other critical military inputs. The 1960s Space Race created a whole generation of aerospace tech firms, while the 2008 financial crisis prompted direct government investment in banks, airlines, and carmakers.
Now, we’re seeing another concerted effort by the government to remake American businesses. Billions of dollars will get injected into certain companies.
And for those seeking an insight into which firms will receive this windfall, watch your inbox on Tuesday, January 27.That’s when we’ll be sending you a direct link to Luke’s free Genesis Missionpresentation.
I’ll see you back here next week.
Thomas Yeung, CFA
Market Analyst, InvestorPlace
RJ Hamster
WARNING: “Something Bigger Than an IPO is Coming”
Editor’s Note: Over the last 25 years, legendary trader Tim Sykes has been featured on CNBC, ABC, Larry King, The Steve Harvey Show and more. Throughout his career, he’s generated more than $7.9 million in profits. Click here to see Tim’s newest warning or read the details below.
Dear Reader,
A little-known change to a massive 25-year policy could soon reshape a $4 trillion market.
Most people have no idea this is happening. But if you have less than $25,000 in your brokerage account…
This NEW policy could open the floodgates for you to participate unlike ever before.
Forget chasing the next hot IPO…
Because one Wall Street insider called this $4 trillion market “a generational buying opportunity.”
GET THE FULL DETAILS AND HOW TO PREPARE NOW, FREE OF CHARGE.
Regards,
Signer
P.S. The AI boom has already minted over 600,000 new millionaires, but this new policy changes everything.
Because this has nothing to do with an IPO, there is NO prospectus available.
You must watch this shocking video now to see the details before it’s too late.
More Reading from MarketBeat.com
These 3 Small-Cap Stocks Are Built to Weather a Slowdown
Author: Chris Markoch. First Published: 1/12/2026.
What You Need to Know
- Falling interest rates tend to give small-cap stocks a stronger performance tailwind than large caps.
- These three small-cap companies combine financial discipline with exposure to industries positioned to benefit as rates decline.
- Investors can use these stocks to build a more selective small-cap strategy that balances upside potential with downside protection.
The Russell 2000 index, commonly called the “small-cap index,” has risen roughly 6% over the past three months. That gain has been driven largely by shifts in interest-rate expectations after the Federal Reserve cut rates by 75 basis points (0.75%) during this period.
Lower interest rates are generally bullish for stocks—especially small-cap stocks. These companies typically face higher borrowing costs and were particularly sensitive to the higher-for-longer rate environment of the past three years.
Trump’s new AI budget just passed — one stock could soar (Ad)
In a quiet move few people noticed…
President Trump just green-lit what could become the biggest AI budget in history.Click here now to discover the name and ticker before this story hits the mainstream >>>
That sensitivity is also why some analysts think the emerging small-cap rally could persist. While the exact number of rate cuts in 2026 is unclear, most observers expect at least some easing. Fed Chair Jerome Powell’s term expires in May, and his replacement is widely anticipated to be more inclined toward additional cuts.
Another factor supporting the expectation of lower rates is the economy’s mixed signals: growth remains uneven even as corporate earnings have been strong. As rate pressure eases, the small-cap winners are likely to be companies with solid balance sheets that can translate improving financial conditions into sustainable growth—not the most leveraged or speculative names.
UFP Technologies: Quality Growth Without Financial Risk
UFP Technologies Inc. (NASDAQ: UFPT) is part of the industrial sector that performed well in 2025. The company manufactures custom-engineered products using plastics, foams and adhesives for industries including medical devices, aerospace and defense, electronics, and transportation.
A common thread across these end markets is an emphasis on precision, compliance and reliability over price alone. That focus is reflected in the company’s revenue and earnings, which have increased year over year. Both the top and bottom lines are projected to grow strongly in 2026.
Unlike many small caps, UFP Technologies has a strong balance sheet and consistent free cash flow that allow the company to fund expansion. Lower interest rates would make it easier for UFP to accelerate the kinds of investments it already makes.
UFPT is essentially flat over the last 12 months but is up about 30% in the past three months. The stock recently broke above its 50-day simple moving average, and the MACD is strengthening. However, the relative strength index (RSI—not shown) is moving into overbought territory, so investors may prefer to wait for a better entry point before buying.
Kulicke & Soffa: Cyclical Upside Backed by Net Cash
The chip-stock supercycle is expected to continue in 2026, and Kulicke & Soffa Industries (NASDAQ: KLIC) offers an under-the-radar way to play that theme. The company specializes in advanced packaging and manufacturing technologies for semiconductors, making it a potential beneficiary of capital expenditure as rates decline.
Kulicke & Soffa maintains a healthy balance sheetwith a strong net cash position. Analysts forecast roughly 86% earnings growth over the next 12 months.
KLIC has risen about 13.4% over the past 12 months and roughly 34% in the last three months, including a strong momentum move during the first five trading days of 2026. That places the shares near the top of their 52-week range. Analysts are generally bullish, but the stock may face short-term pullback risk.
Gibraltar Industries: Rate Sensitivity Without Leverage
Gibraltar Industries Inc. (NASDAQ: ROCK) is an infrastructure play that would normally benefit from lower interest rates. Instead, ROCK is down about 23% since the Fed began cutting rates.
The decline appears largely tied to delays in a controlled-environment agriculture project, which raised valuation concerns. That headwind should be temporary: the company reports an expanding backlog that could translate into improved revenue and earnings, particularly in the second half of 2026.
Investors also benefit from Gibraltar’s conservative capital structure, which helps it navigate slowdowns without resorting to asset sales or dilutive equity issuance. As financing becomes more accessible, the company is positioned to benefit from improving construction and infrastructure activity while maintaining financial discipline.
This email message is a sponsored message provided by Millionaire Pub, a third-party advertiser of MarketBeat. Why did I receive this email message?.
If you need help with your newsletter, feel free to contact MarketBeat’s South Dakota based support team at contact@marketbeat.com.
If you would no longer like to receive promotional emails from MarketBeat advertisers, you can unsubscribe or manage your mailing preferences here.
© 2006-2026 MarketBeat Media, LLC.
345 North Reid Place #620, Sioux Falls, S.D. 57103-7078. United States..
Read More: Buffett, Gates and Bezos Quietly Dumping Stocks—Here’s Why (From Banyan Hill Publishing)
RJ Hamster
The Stock DC Could Buy Next (Ticker Inside)
Dear Reader,
The U.S. government is about to launch a historic stock market buying spree.
But this time, it won’t be rare earth or natural resource stocks suddenly exploding 200%+ higher…
It’ll be a surprising NEW group of ‘National Priority’ stocks.
And I just named them all for you, on camera, free of charge.
It all boils down to an official government National Security plan I’ve seen, which lays out – in detail — exactly why the government is rapidly taking stakes in little known stocks.
For instance, when the U.S. government bought Trilogy Metals, the stock tripled overnight.
You could have doubled your money on 28 stocks connected to this story in 2025 alone.
But I believe there’s a second phase to this plan coming very soon — which could be hugely profitable, if you own the right stocks.
And that’s why I’m doing something unusual…
I just appeared on camera and NAMED more than 100 different stocks that are likely to be targeted next.
You read that right:
I’m giving you dozens of stock tickers that are key to this story – free of charge.
I have no idea how long I’ll be allowed to give this information away for free.
But if you’re quick… this information could be worth thousands of dollars to you, starting immediately.
Just know this:
The next group of stocks White House insiders are likely to target will surprise you.
But there’s no better chance to double or triple your money — quickly — than buying these stocks today.
Regards,
Luke Lango
Senior Investment Analyst, InvestorPlace
This ad is sent on behalf of InvestorPlace Media at 1125 N. Charles Street, Baltimore, Maryland 21201. If you’re not interested in this opportunity, please click here.Stockguru LLC (dba InvestingDistrict), 2563 cherry hill ln, Hermitage, PA 16148, United StatesYou may unsubscribe or change your contact details at any time.
RJ Hamster
Investing Ideas Daily
Investing Ideas Daily
— Read on investingideasdaily.com/
RJ Hamster
PSTR studio | Premium Fine Art
Discover premium fine art prints from emerging artists worldwide! Our art posters are produced through the sophisticated giclée printing process on luxurious matte paper, sourced from sustainably forestry. Enjoy vibrant colors, stunning details, and free framing service with every order.
— Read on www.pstrstudio.com/
RJ Hamster
Put $1,000 into this stock NOW [Not NVDA]
Dear Reader ,
The legendary quant who built one of Wall Street’s most popular buying indicators just announced the #1 stock to buy for 2026.
And for a limited time, he’s sharing this new recommendation live on-camera, completely free of charge .
He spent 50 years working alongside legendary investors like George Soros, Michael Steinhardt, Steve Cohen, and Paul Tudor Jones.
His work is coded into every Bloomberg terminal on Wall Street, and is still used by hundreds of banks, brokerages, and hedge funds to this day.
So why is he giving away his #1 buy recommendation for FREE?
It’s all comes back to a shocking new market prediction for 2026 .
This same legend – who accurately predicted the 2020 covid crash, the 2022 bear market, and the 2023 bank run – is now calling for an abrupt, surprising shift in the U.S. stock market .
The last time this happened, average investors lost over a fifth of their portfolio in just a matter of months.
So I got him to agree to an exclusive sit-down interview, where I got the whole story.
You’ll get his #1 buy recommendation for 2026 when you click here .
To pick these recommendations, he consulted the same system that he used when CNBC’s Jim Cramer said he’d never bet against him.
So I urge you to take advantage before it’s too late.
Go here now to see the names and tickers while you can .
Regards,
Kelly Brown
Host, Chaikin Analytics
This ad is sent on behalf of Chaikin Analytics, 201 King Of Prussia Rd., Suite 650, Radnor, PA 19087. If you would like to optout from receiving offers from Chaikin Analytics please click here.Stockguru LLC (dba InvestingDistrict), 2563 cherry hill ln, Hermitage, PA 16148, United StatesYou may unsubscribe or change your contact details at any time.
RJ Hamster
In 5 hours, the trades go out
In just five hours, Weekend Trader Alert subscribers are going to receive their next set of trades.
The same kind of setups that delivered a 559.8% gain over the last three months, driven by results like the ones you see below:
These are all real trades, executed week by week, using the same structure subscribers will receive tonight.
Here’s what hits inboxes at 7 p.m. ET:
- Up to 2 option trades — complete with the exact option, entry window, profit objective, time stop, and trade rationale
- Low-cost options — most premiums under $20, many under $5, with risk defined before the trade starts
- Manageable holding periods — positions typically held one to four months
- Clear objective — every trade targets a 100% gain
That’s the entire framework… and it happens every Sunday.
That’s everything you’re about to miss out on. 5 hours to decide…
Best,
Bernie Schaeffer
Founder & CEO
Schaeffer’s Investment Research
🌐 http://www.schaeffersresearch.com
📞1-800-448-2080
International 1-513-589-3800
Update your email preferences or unsubscribe here
© 2026 Schaeffer’s Investment Research
5151 Pfeiffer Road, Suite 450
Cincinnati, Ohio 45242, United States of AmericaTerms of Service
RJ Hamster
The Ancient Secret Behind Modern Market Timing
The Ancient Secret Behind Modern Market Timing
BY KEITH KAPLAN
CEO, TRADESMITH
Human progress didn’t start with better tools. It started with better timing.
Early humans paid close attention to repeating patterns in nature – the length of days, the return of floods, the timing of animal migrations.
Those observations gave rise to the first calendars – sometimes recorded in stone and often anchored to the predictable cycles of the sun, moon, and stars.
This helped early farmers decide when to plant and harvest crops and helped hunters know when herds would pass through a region.
These cycles didn’t explain whythings happened. They explained when things happened. And that knowledge was enough to plan around.
And when it comes to humanity’s long fascination with cycles, few monuments are as widely studied as Stonehenge in southern England.
Stonehenge, a prehistoric monument near Salisbury in southern England
Built about 4,500 years ago in several phases, Stonehenge is among the best-known prehistoric monuments.
One enduring theory about Stonehenge rests on its alignment. Its main axis points toward the sunrise on the summer solstice. That’s led archaeologists to argue that Stonehenge was designed, at least in part, to mark key points in the solar year – signals that would have helped early societies anticipate seasonal change in a world where timing meant survival.
Building a monument like this likely required generations of careful observation, tracking the sun’s annual path using little more than fixed landmarks and sightlines.
Today, we don’t need to build huge stone structures to detect patterns that can help us thrive. We have more detailed data at our disposal and a lot more analytical power to help us put it all together.
At TradeSmith, our mission is to give everyday investors access to the kinds of data and analytics once reserved for hedge funds. That work has led us to uncover a feature of the market that’s often overlooked: seasonality in stock movements.
You can’t see these cycles with the naked eye. They only show up after you run decades of data through powerful algorithms to look for them.
But once you do, a surprising picture emerges.
Thousands of stocks have historically reliable windows – specific times of year when they tend to rise and others when they tend to fall. That includes bull and bear markets, manias and panics, wars, pandemics, and more.
And I’m proud to say that, at TradeSmith, we’ve developed cutting-edge software to track those seasonal patterns. We’ve also created a rapid-fire trading strategy based on these signals that can pinpoint bullish seasonality windows on 5,000 stocks – to the day. In our backtests, the system’s trades have won with 83% accuracy.
Now, in our next phase, we’re about to release a seasonal portfolio strategy that’s turned every $10,000 into $85,700 in our backtests.
You can find out everything you need to get started by watching the replay of our Prediction 2026 webinar – while it’s still available. The next seasonal reversal is set to hit as soon as Jan. 28. So if you missed it, now’s the time to catch up.
Then read on for more on the seasonality phenomenon in markets and how, over the last 15 years, some stocks have followed their seasonality windows with 100% historical accuracy.
Recommended Link
Buy this stock for 2026 (And sell this one)
Will you potentially make money or lose money in the U.S. stock market in 2026? According to the 50-year Wall Street legend who invented one of Wall Street’s most popular buying and selling indicators – the answer has nothing to do with AI, quantum computing, or cryptos. Instead, it all comes down to the #1 stock he recommends you BUY now… And the #1 stock he recommends you SELL now.
Seasonality Affects Markets, Too
Commodity traders, for example, have long tracked planting and harvest cycles in crops like corn and wheat.
Energy traders watch seasonal demand shifts tied to winter heating and summer cooling.
The gold market has recurring seasonal tendencies, often strengthening during certain parts of the year tied to jewelry demand, central bank buying, and annual festivals in India and China.
And stock investors have studied phenomena like the January Effect for decades. Even Wall Street’s old saying – “Sell in May and go away” – comes from observed seasonal behavior, not theory.
But we’ve discovered that seasonality doesn’t just apply just to commodities and the big stock market index. Every stock has its own seasons to rise or fall – a kind of summer and a kind of winter, too – year after year.
Big-box retailer Target (TGT) provides a good example.
As one of America’s largest retailers, this stock moves with the rhythms of consumer spending throughout the year. But for all the money won – and lost – on Target over the last few years, there’s one certainty…
Between June 22 and July 21, you want to buy the retail bellwether. Target has moved up an average of 5.2% during that summer period, rising 100% of the time over the past 15 years:
That’s 15 years of summertime price spikes, starting long before it fell under the pandemic-era spotlight. And in 2025, the pattern held true: Target rose 10.3% during its 29-day seasonally bullish window.
The chart you’re seeing above is from one of the breakthrough innovations from TradeSmith’s team of researchers, software engineers, and quant investors: our ground-breaking Trade Cycles Seasonality tool.
It’s an easy-to-use tool that can take one of thousands of commonly traded stocks, analyze its movements, and point out its strongest seasonality trends – with starting periods narrowed down to the day.
Here’s another example of a strong seasonality pattern, this time in Home Depot (HD):
Over the last 15 years, between June 15 to July 27, Home Depot’s share price has risen 93% of the time, with an average return of 4.7%.
And in 2025, the pattern held true again. It rose from $349.31 on June 16 to $372.69 on July 28 – a 6.7% gain in a just over a month.
A Powerful New System for Seasonal Profits
Target and Home Depot are just two examples among many others.
Our development team has fine-tuned this tool to uncover seasonality cycles in stocks, stock market indexes like the S&P 500 and the Nasdaq, as well as in currencies and commodities.
By crunching the data and compiling the historical movements of thousands of different assets and running 50,000 tests a day to analyze every stock in the major indexes, we’ve built a new system to help predict the biggest jumps on 5,000 stocks.
Over our 18-year backtest, these seasonal trades delivered 857% in total growth. That’s more than twicewhat the S&P 500 delivered over the same time.
Even in 2007, the worst year in our testing, we saw an average gain of 2.5% and an annualized return of 37.9%. That’s close to four times the average annual gain of the S&P 500.
The question now is: How can we make this powerful system work for you?
The Power of Seasonality Is Now in Your Hands
That’s why, if you missed it, I hope you’ll check out the replay of our Prediction 2026 event.
I’ll walk you through how we discovered these hidden seasonal patterns using cutting-edge technology, why seasonal patterns keep working even in bear markets…
And how our Seasonality tool can help you find the best time to buy and sell a stock – down to the day.
A new batch of these seasonal cycles could be about to kick off next Wednesday, Jan. 28…
And if this pattern plays out as expected, it’d unlock one of the best trading setups we’ve seen in decades.
So check out the replay while there’s still time.
All the best,
Keith Kaplan
CEO, TradeSmith
RJ Hamster
Elon Taking SpaceX Public! $100 Pre-IPO Opportunity!
A message from Paradigm Press
Below is an important message from one of our highly valued sponsors. Please read it carefully as they have some special information to share with you.
Dear Reader,
It’s official…
SpaceX is going public…
And they’re saying it could be anywhere from $800 billion…
To $1.5 TRILLION!
To date, the biggest IPO ever was Saudi Aramco… at a mere $25.6 billion.
That means…
SpaceX’s IPO could be 58X BIGGERthan the largest IPO in history.
Wall Street insiders are salivating at this massive stock move.
But here’s the thing…
You do NOT have to be left out of this once-in-a-lifetime opportunity.
In fact, you can get action on this SpaceX IPO right now – before it goes public, in a regular brokerage account …
And you can get into this play for less than $100.
Click here for the full story.
It sounds nuts…
But this is your chance to beat Wall Street to the punch…
And get a piece of the action on the BIGGEST IPO in history…
Before the news even hits the market.
Do NOT miss this opportunity.
Click here to learn how to claim your stake NOW.
Best,
Matt Insley
Publisher, Paradigm Press
Special Report
High Risk, High Reward: 3 Healthcare Stocks to Watch in 2026
By Nathan Reiff. Posted: 1/19/2026.
What You Need to Know
- Three biotech names with promising clinical trial data and a history of revenue generation stand out from the broader field for 2026.
- Atai Beckley and Evommune have promising pipelines focused on mental health disorders and inflammatory disease treatments, respectively.
- CorMedix has proven success with its catheter lock products and is expanding beyond the hemodialysis space in compelling ways.
Last year, the biotechnology industryleaned heavily into artificial intelligence (AI), using machine learning to identify drug targets, optimize molecules and predict trial outcomes. Alongside the continued spread of technology within the drug-development space, companies focused on obesity, rare diseases and oncology posted notable commercial achievements.
Heading into 2026, the landscape could continue to reward investors willing to accept higher risk. Lower interest rates and improved funding conditions may drive more investment in biotechs, particularly those with clear paths to commercialization. Many of the standout biotech stocks to watch in 2026 have tangible catalysts that could drive growth.
Atai Beckley: Potential Treatment for Major Mental Health Disorders
Best $19 you’ll spend this year. (Ad)
A former hedge fund manager known for cutting through market noise is briefly opening access to his flagship trading strategy. In a short demo, he explains how his “One Ticker” approach works — and how readers can access the full service for a year at a steep discount.Watch the brief demo here
Atai Beckley (NASDAQ: ATAI) develops therapies for mental health disorders, including treatment-resistant depression (TRD) and substance use disorders. Shares of this small-cap stock rose roughly 175% over the past year, despite a pullback in the final weeks of 2025. Investor enthusiasm in recent quarters was driven in part by the combination of atai Life Sciences and Beckley Psytech and a redomiciliation to the United States.
Investors should watch Atai Beckley for updates on BPL-003, a nasal spray in development for TRD and alcohol use disorder that reported positive topline results in a Phase 2b trial last July and additional promising data in November. A Phase 3 trial is expected to begin in the second quarter of 2026. The company’s pipeline is sizable and also includes other TRD candidates as well as a potential treatment for social anxiety disorder.
ATAI’s clinical momentum and the market opportunity are significant, but the company must manage high R&D expenses and very modest revenue. For that reason, 2026 could be a make-or-break year. Investors willing to take a chance on a promising TRD treatment may reap substantial rewards, but risk remains elevated.
Hemodialysis Wins and Expansion Could Drive CorMedix in 2026
We previously highlighted CorMedix Inc. (NASDAQ: CRMD) for its leadership in the catheter-lock market, where its DefenCath has shown potential to reduce catheter-related infections and hospitalizations among dialysis patients. The company’s potential blockbuster, however, may be REZZAYO, a treatment for candidemia that is currently in a Phase 3 trial, with data expected next quarter.
CorMedix is also expanding beyond hemodialysis, including its recent acquisition of Melinta Therapeutics, which is known for fungal and bacterial infection treatments. Melinta’s portfolio contributed roughly $13 million in sales in September alone, and the acquisition could provide an additional revenue lift when CorMedix reports full-year results.
The firm’s strong third-quarter 2025 results, which showed notable top- and bottom-line gains, along with a healthy cash position, should help buffer the company as healthcare reimbursement pressures persist in the coming year. That strength is reflected in analysts’ views: the consensus price target for CRMD is $17.86, about 153% above current levels.
Evommune: New Entrant with Upside in Atopic Dermatitis
Focused on chronic inflammatory diseases, Evommune (NYSE: EVMN) is the newest biotech on this list. The company went public in November 2025, and shares have climbed nearly 14% in the first two months of trading. Because it is newly public, investors have less historical data to evaluate, but there are reasons to expect 2026 could be a breakout year.
In the third quarter of 2025—the only quarterly report Evommune has filed since its IPO—the company highlighted Phase 2 data readouts for EVO756 and EVO301, aimed at chronic inducible urticaria and certain forms of atopic dermatitis, respectively. Top-line results from both trials are expected in early 2026 and could serve as significant catalysts.
Evommune ended the third quarter with a modest but healthy cash balance of $76 million and has begun generating revenue through a licensing agreement in Japan. Still, R&D expenses are likely to remain high. Analysts are optimistic about EVMN’s prospects, projecting more than 84% potential upside.
Thank you for subscribing to StockReport.com, our daily newsletter that highlights a new stock each day.
This email communication is a sponsored message for Paradigm Press, a third-party advertiser of StockReport.com and MarketBeat.
If you have questions about your account, don’t hesitate to contact us at contact@stockreport.com.
If you no longer wish to receive email from StockReport.com, you can unsubscribe.
Copyright 2006-2026 MarketBeat Media, LLC dba StockReport.com.
345 North Reid Place, Sixth Floor, Sioux Falls, SD 57103-7078. United States of America..